Rituximab
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Explore 39 assets in Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
OHSU Knight Cancer Institute
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT03576547CT.gov Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia | — | Terminated | — | — | — |
NCT03147612CT.gov Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT01670084CT.gov Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia | — | Withdrawn | — | — | — |
NCT01424982CT.gov Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT01044745CT.gov Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rituximab (this asset) | OHSU Knight Cancer Institute | P2 | BB · 64 |
| Fludarabine | Ohio State University Comprehensive Cancer Center | P2 | BBB |
| Cyclophosphamide | Ohio State University Comprehensive Cancer Center | P2 | BBB |
| Tacrolimus | University of Michigan Rogel Cancer Center | P2 | BB |
| Imatinib | The University of Hong Kong | P2 | BB |
| Nilotinib | The University of Hong Kong | P2 | BB |
| Busulfanum | Fred Hutchinson Cancer Center | P2 | BB |
| Romidepsin | M.D. Anderson Cancer Center | P2 | BB |
| (+)-Vincristine | OHSU Knight Cancer Institute | P2 | BB |
+42 more in the Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive cohort
Other indications for Rituximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoblastic Lymphoma | — | P4 | BBB · 75 |
| Grade III Lymphomatoid Granulomatosis | — | P2 | BBB · 74 |
| Testicular Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rituximab in Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g-1-human-mouse-monoclonal-idec-c2b8-gamma1-chain-anti-human-antigen-cd-20-disulfide-with-human-mouse-monoclonal-idec-c2b8-kappa-chain-dimer-blast-phase-chronic-myelogenous-leukemia-bcr-abl1-positive
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →